Navigation Links
SeqWright's Clinical Trial Support Contributes to the Approval of Two HPV Diagnostic Systems
Date:4/7/2009

HOUSTON, April 7 /PRNewswire/ -- SeqWright Inc., an international leader in the field of contract genomic services, announced today its involvement in Hologic's (formerly Third Wave Technologies) successful clinical trials of two Human Papillomavirus (HPV) in vitro diagnostic tests. SeqWright provided FDA submission quality DNA sequencing of multiple HPV strains and bioinformatics support to validate two Hologic HPV diagnostic tests; Cervista HPV High Risk (HR) and Cervista HPV 16/18, in preparation for FDA submission. Both tests were recently awarded FDA premarket approval. According to Hologic, their Cervista HPV HR clinical trial involved over 4,000 women spread across 89 sites throughout the United States and constituted one of the largest and most demographically diverse clinical trials ever conducted in the United States.

SeqWright was selected to perform the sequencing-based validations of Hologic's HPV Diagnostics assays after successfully completing several of Hologic's previous clinical trials, which all led to FDA approvals. SeqWright maintains advanced quality control with a Clinical Laboratory Improvement Amendment (CLIA) certification as well as maintaining compliance with Good Laboratory Practices (GLPs) as specified in the Code of Federal Regulations.

Sequencing for Hologic's clinical trials was performed under GLP guidelines (4X-bidirectional sequencing, stringent controls, full documentation) and all samples were continuously tracked and monitored. The bioinformatics provided by SeqWright were also vital to trial success and were used to implement Hologic's HPV genotyping analysis as well as to create a customized clinical trial decision tree algorithm. These services led to a streamlined, reliable and efficient testing regimen in support of Hologic's two recently approved HPV Diagnostics.

SeqWright CEO, Dr. Fei Lu, M.D. stated, "We wish to congratulate Hologic on the
'/>"/>

SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 17, 2014 ... ) has announced the addition of ... American Automated External Defibrillators (AED) Market" ... http://photos.prnewswire.com/prnh/20130307/600769) ,The report North American Automated ... market of devices based upon following ...
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... , Oct. 17, 2014  Talyst, a market leader ... LeadingAge Annual Meeting in Nashville, TN. ... the market leading solution for onsite, remote medication dispensing. ... care facilities to safely and securely dispense medication onsite, ... first dose, helps ensure that the correct medication gets ...
Breaking Medicine Technology:Micro Market Monitor : North American Automated External Defibrillators (AED) Market 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2
... Feb. 21, 2012 ConvaTec, a world-leading developer and ... care, today announces that Ken Berger will assume the ... the ConvaTec Board of Directors. Berger joins ... last ten years, most recently as Senior Vice President ...
... Feb. 21, 2012  Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX ... overview at the Citi Global Healthcare Conference on February 27, ... New York City.   The live and archived ... of Events" in the Idenix Investor Center at ...
Cached Medicine Technology:ConvaTec Announces the Appointment of Ken Berger to the Position of CEO Effective March 6, 2012 2
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... 20, 2014 Myoderm ... Assistant Director of their CentralSource service. ... the innovative turnkey drug sourcing, distribution, and management ... over 12 years of industry experience, in both ... the peak of their international success to help ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Succeed is proud ... local companies who participated in the Every Body Walk! ... a public awareness project that encourages workers to be more ... Step 10,000 Program, which concluded at the end of September, ... of cities and metro areas. Participating companies gave their ...
(Date:10/20/2014)... 20, 2014 National Teen Driver Safety Week ... American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is ... parents of teen drivers to talk to their teens and ... Motor vehicle crashes are the leading cause of death for ... in fatal crashes, and 859 (42%) of those teen drivers ...
Breaking Medicine News(10 mins):Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2
... Nearly one in three women who have breast cancer ... additional surgery after the tumor is evaluated by a pathologist. ... Cancer Center cuts that number drastically by having pathologists on-site ... immediately after they are removed. Meanwhile, the surgeon and patient ...
... News) -- Drug-free recovery housing and day treatment programs ... who have gone through detoxification will be able to ... abuse includes both the use of illegal drugs such ... such as OxyContin, Vicodin and Percocet. Opioid addicts ...
... alone, approximately 6 million people suffer from an irregular ... with age, it is predicted that 15.9,million Americans will ... of AF is stroke, but,a new device from Boston ... Atritech, now part of Boston Scientific, developed the WATCHMAN ...
... MONDAY, Feb. 27 (HealthDay News) -- Many people with stable ... work just as well, a new study suggests. The ... a clogged artery. As many as three-quarters of these operations ... professor of medicine at Stony Brook University Medical Center in ...
... A great deal has been learned in the ten years ... (WHI). Hormone therapy (HT) remains the most effective treatment available ... a growing body of evidence that formulation, route of administration, ... effects. It is essential to evaluate a personal ...
... the country tripled to nearly three per year between 1994 ... 15 years, according to an analysis of weather conditions and ... Georgia researchers. The scientists built a detailed database ... well as the height, weight and position for 58 football ...
Cached Medicine News:Health News:Fewer women need repeat breast cancer surgeries with new service at University of Michigan 2Health News:Drug-Free Housing Helps Heroin, Oxycontin Addicts Recover 2Health News:Stroke-preventing technology demonstrated in JoVE 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 2Health News:Stents No Better Than Medicine for Stable Heart Disease, Study Says 3Health News:The North American Menopause Society (NAMS) reassures many women 2Health News:Deaths triple among football players, morning temperatures thought to play a role 2